In a study of glioma cells in nude mice, EMAP-II showed specific toxicity in vitro against GECs and, as an anti-angiogenic therapy, it stopped glioma growth as a tumor blood vessel inhibitor and by VEGF inhibition (Schwarz and Schwarz, 2004). This evidence concerns the gene VEGFA and central nervous system cancer.